Phase: Phase IV
Type: Health services research, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 240293, NCT01698177

Phase: Phase III, Phase II
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 5, NCT01509612

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR003583, ET743SAR3002, NCT00210665

Phase: Phase III
Type: Diagnostic
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: R05-0076, NCT00207298

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 21
Sponsor: Other
Protocol IDs: CCLG-EPSSG-NRSTS-2005, EU-20620, EUDRACT-2005-001139-31, UKCCSG-CTA-21275/0215/001/0001, CCLG-EpSSG-STS-2006-03, NCT00334854

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 50
Sponsor: NCI, Other
Protocol IDs: CDR0000487560, COG-ARST0531, ARST0531, NCT00354835

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: CRUK-VORTEX, EU-20678, ISRCTN76456502, CRCTU-SA3002, NCT00423618

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: SCUSF-0703, MCC-0703, SCUSF 0703, NCT01132547

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08SARC01, NCT00870701

Phase: Phase III
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: CWS-2007-HR, 4033024 (BfArM), 293/2007AMG1 (Ethikkommission), 2007-001478-10, A2007/14 (Kinderkrebsstiftung), 498 (Krebsstudienregister), NCT00876031

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-154, NCT01223248

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7389-G000-309, NCT01327885

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000699225, EORTC-62092, EORTC-22092, EU-21113, STRASS, NCT01344018

Phase: Phase III
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR018004, ET743SAR3007, NCT01343277

Phase: Phase III
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TH-CR-406/SARC021, NCT01440088

Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 09-0855-C, CIHR, NCT01506492

Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7040-J081-301, NCT01677624

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR017269, ET743SAR3006, NCT01692678

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ISG-STS 10-01, NCT01710176

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 72
Sponsor: Other
Protocol IDs: GEIS01-07, NCT00541840

Phase: Phase II, Phase I
Type: Tissue collection/Repository
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 93-102, NCT00579163

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: ASSG01, NCT00753727

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000628781, UCDCC-216, BAYER-UCDCC-216, NCT00805727

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AVF4761s, 200911736, NCT01106872

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01412, 10-049, CDR0000680558, MSKCC-10049, U01CA069856, 8406, NCT01154452